title: Modulation of major histocompatibility complex antigens and inhibition of proliferative activity of YAC lymphoma cells by a natural killer lysis resistance-inducing factor (NK-LRIF).
abstract: Concanavalin-A-activated rat spleen cells secrete a natural killer lysis resistance-inducing factor (NK-LRIF) distinct from interleukin-2 and interferon, which induces resistance to NK-cell-mediated lysis in YAC tumor cells. In order for NK-LRIF to have an effect on YAC cells, several hours of incubation is required. When NK-LRIF-treated YAC cells are washed and cultured in the absence of NK-LRIF, normal NK susceptibility is regained. YAC cells treated with NK-LRIF show a significant decrease in the rate of proliferation as judged by changes in cell numbers and rate of thymidine incorporation. Cell cycle studies indicate that the proportion of G0/G1 phase cells increases in YAC preparations treated with NK-LRIF. Major histocompatibility complex (MHC) class I antigen expression is markedly enhanced on YAC cells incubated with NK-LRIF but the expression of MHC class II antigens and Thy-1 antigen remains unchanged. No effect of NK-LRIF treatment on the capacity of YAC cells to bind effector spleen cells could be demonstrated.
authors.affiliation: Immunology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
authors.forename: R K
authors.initials: RK
authors.lastname: Saxena
authors.forename: F J
authors.initials: FJ
authors.lastname: Chrest
authors.forename: W H
authors.initials: WH
authors.lastname: Adler
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D000954:Antigens, Surface / Q000096:biosynthesis; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003602:Cytotoxicity, Immunologic; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006649:Histocompatibility Antigens / Q000096:biosynthesis*; D008214:Lymphocytes / Q000032:analysis; D008222:Lymphokines / Q000302:isolation & purification / Q000494:pharmacology*; D008223:Lymphoma / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D018800:Thy-1 Antigens; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D006649:Histocompatibility Antigens; D008222:Lymphokines; D018800:Thy-1 Antigens